Aller au contenu principal
2024 conference-abstract

GATA1 Insufficiencies in Dysmegakaryopoiesis of Myelodysplastic Syndromes/Neoplasms

0Citations signalées, ce qui n’est pas une note de qualité
3Institutions déclarées
2Pays d’affiliation déclarés

Rattachement africain : cn, gb. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Introduction: GATA1 is one of critical transcription factors for megakaryopoiesis and platelet production. Our study aimed to explore the correlations between GATA1 expression and dysmegakaryopoiesis in myelodysplastic syndromes/neoplasm (MDS). Methods: Data of blood cell counts, cytogenetics and next-generation sequencing from 90 MDS patients at diagnosis were collected. Firstly, we assessed GATA1 expression level of megakaryocytes by performing immunohistochemical staining on bone marrow biopsy sections from the aforementioned 90 MDS patients. According to GATA1 expression level of megakaryocytes and positive megakaryocyte percentage, we assigned each patient a GATA1 score. Furthermore, we explored the correlation between GATA1 expression levels and cytogenetic abnormalities of the same megakaryocytes using the morphology antibody chromosome (MAC) technique on fresh bone marrow smears from another 6 MDS patients. To explore the significance of GATA1 expression levels in the prognosis of MDS, we included GATA1 scores in a multivariable analysis of overall survival (OS). Results: Patients with abnormal karyotypes showed decreased GATA1 scores than those with normal karyotypes (6.0 [3.0-10.5] versus 12.0 [4.0-12.0] scores, P = 0.024). Compared with TP53-wildtype patients, GATA1 scores significantly decreased in TP53-mutated patients (3.0 [2.3-6.0] versus 12.0 [6.5-12.0] scores, P < 0.001). However, patients with mutations of other genes showed no significant differences in GATA1 scores compared with wildtype patients (P > 0.05). GATA1 expression levels were significantly downregulated in dysplastic megakaryocytes, especially micromegakaryocytes (P < 0.001). Furthermore, we found that GATA1-negative megakaryocytes had higher frequencies of cytogenetic abnormalities (87.5% versus 47.6%, P = 0.002) using MAC technique. The multivariable analysis of overall survival that lower GATA1 scores (P = 0.005) were significantly associated with inferior OS in MDS, independent of the IPSS-R higher-risk category (IPSS-R scores > 3.5 points). Conclusion: Our results indicated that decreased GATA1 expression level of megakaryocytes was significantly associated with TP53 mutations, abnormal karyotypes and dysmegakaryopoiesis in MDS, suggesting that downregulation of GATA1 expression levels of megakaryocytes plays a critical role in the pathogenesis of MDS.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
GATA1 Insufficiencies in Dysmegakaryopoiesis of Myelodysplastic Syndromes/Neoplasms
Date Crossref
05/11/2024
Éditeur
American Society of Hematology
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Neurogenetic and Muscular Disorders ResearchRNA modifications and cancerCongenital heart defects research

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.